This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jones, R. J. Articles by Sensenbrenner, L. L. Search for Related Content PubMed PubMed Citation Articles by Jones, R. J. Articles by Sensenbrenner, L. L.

Prediction of the Ability to Purge Tumor from Murine Bone Marrow Using Clonogenic Assays¹

The Johns Hopkins Oncology Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205

The development of potential purging regimens for autologous bone marrow transplantation has been limited by the inability to predict the antitumor activity of these regimens at doses which will allow engraftment. We describe an in vitro model which estimates the in vivo efficacy of potential purging regimens in mice. The log kill of clonogenic L1210 cells after in vitro incubation with graded doses of 4-hydroperoxycyclophosphamide and vincristine (alone or in combination) was linearly related to the incubation dose of drugs. Clonogenic assays could only directly demonstrate about three logs of cell kill. However, the log linear dose-response allowed the extrapolation of cell kill for doses of drugs whose kill could not be determined directly. The extrapolated cell kill accurately predicted the in vitro activity of the drugs as established by determining the survival of B6D2F₁ mice given injections of the drug-treated L1210 cells. Lethally irradiated B6D2F₁ mice were given injections of mixtures of syngeneic bone marrow and L1210 cells purged with a combination of 4-hydroperoxycyclophosphamide and vincristine. Combining the results of in vitro granulocyte-macrophage colony-forming unit and clonogenic L1210 sensitivities to this drug combination predicted the survival of mice and, therefore, the effectiveness of the purging regimen.

¹ Supported in part by American Cancer Society Grant CH-369.

² To whom requests for reprints should be addressed at The Johns Hopkins Oncology Center, 600 N. Wolfe Street, Baltimore, MD 21205.

Received 12/21/87. Revised 3/18/88. Accepted 3/21/88.